microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft product information management software  plytix pricing solutions product information manager product analytics tool about about us blog press contact sign in get started your product content hub manage optimize and distribute your product content from one cloud platform to get to market faster   x features pricing testimonials launch products faster eliminate the time consuming tasks that holds you back launch products x faster by enriching optimizing and distributing product content from one location crosschannel coherence over half of all shoppers research products on multiple channels before making a purchase with consistent quality product information potential customers will become loyal customers turn spreadsheets into workspace the plytix pim takes all the data you have buried in spreadsheets with smart import mapping get a workspace that lets you add text media and define custom attributes errorfree digital asset management make sure all your product and brand assets are organized and easily accessible by your whole team link images videos pdfs and other files to products without needing duplicate content  digital product catalogs create interactive download centers for your catalogs share them via public link or embed them directly onto your website catalogs are enhanced with email notifications so that you know where all your content goes be the master of your content take control of your product content and see the difference in your bottom line rich consistent content plus the efficiency provided by a pim can boost sales by   get the full feature  pricing list experience the difference other pim systems are complicated and expensive plytix offers affordable readytouse product information management software that is simple enough for entire teams to use and powerful enough to support limitless growth     i finally have one place for all of my data thats always updated and available to me no matter where i am mai johansson  mai copenhagen growth estimate price per month number of products no credit card required pay as you grow all features included unlimited users unlimited variations xml template builder digital asset management onboarding assistance available type number of products here enterprise customideal for  products need something different let’s talk all features included fixed price per month dedicated account manager integration support free onboarding helloplytixcom bernhard bangs allé   frederiksberg denmark          solutions multichannel product distribution plytix for brands plytix for retailers software product information manager product analytics tool resources what is pim pim vs dam analytics tool comparison product updates support terms and conditions plytix about us blog press career contact our site uses cookies by continuing to browse this site you are agreeing to our use of cookies more information close biomark capital home biomark capital provides venture funding and assistance to early mid and latestage life science companies we target companies with novel approaches to diagnostics therapeutics medical devices and digital health that will change the face of healthcare innovation in the future we share the drive and vision of our portfolio companies to collaborate with them in accelerating growth and building successful business ventures our mission is to improve the human condition by investing our capital and expertise to create value for the most promising life science companies team — biomark capital david wetherell scroll down david wetherell david wetherellmanaging partnerdavid wetherell has spent  years as a ceo in hightech as well as  years in venture capital the last seven of which have been dedicated to biotech and life sciences from  to  he served as both ceo and later chairman of cmgi where he helped build the company from  million in annual revenues to more than  billion and started the first venture capital firm focused on the internet ventures in  due to the mapping of the human genome and demographic trends wetherell turned his attention to the life sciencesin  he started gbp capital a venture capital company focused exclusively on leading edge life sciences wetherell has received numerous awards including ernst  youngs new england entrepreneur of the year in  and recognition as one of money magazines top  investors he obtained his ba in mathematics from ohio wesleyan university and an honorary doctorate from bryant university he currently serves as chairman of lentigen and sits on the boards of numerous other companies including hypermed strand quintess and whiteglove healthdavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei douglas lind douglas lind douglas lindmanaging directordouglas lind joined biomark capital in november  previously he served as managing director at burrill  company and gbp capital a greenwich connecticutbased healthcare venture firm he has more than  years experience in the life sciences industry ranging from the practice of clinical medicine to work as a top tier wall street equity research analyst and venture capitalist throughout his career he has focused on identifying promising disruptive technologies and visionary leadership that offer high value solutions to pressing medical needs he served as senior biotechnology equity research analyst at morgan stanley from  through  and at painewebber from  to  his coverage of large and small capitalization biotechnology companies included amgen biogen celera acquired by quest diagnostics centocor acquired by johnson  johnson chiron acquired by novartis idec pharmaceuticals acquired by biogen imclone acquired by bristolmyers squibb medimmune acquired by astrazeneca agouron acquired by warner lambert axys pharmaceuticals acquired by celera and millenium pharmaceuticals acquired by takeda pharmaceuticalsdr lind is a graduate of the university of iowa college of medicine he served as an attending physician at st elizabeths hospital in boston a major teaching affiliate of tufts university school of medicine where he completed residency training in internal medicine he currently serves on the board of directors of lentigen and hypermed imagingdavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei bryant fong bryant fong bryant e fongmanaging directormr fong joined biomark capital in  prior to biomark capital mr fong was a managing director and general partner at burrill  company where he spent almost  years investing in and managing investments in private and public companies in the biotechnology industry some of mr fong’s recent investments include pharmasset vrus novadaq technologies nvdq galapagos glpg ceptaris therapeutics acquired by actelion and ferrokin biosciences acquired by shire prior to joining burrill  company mr fong held positions as a research scientist with two early stage biotechnology companies located in the san francisco bay area mr fong currently serves on the boards of directors of a number of life science companies including adma biologics adma neos therapeutics neos jhl biotech tt and idx  mr fong earned his bachelors degree with honors in molecular and cell biologybiochemistry from the university of california berkeleydavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei sergey axenovich sergey axenovich sergey axenovichdirectorsergey axenovich joined biomark capital in november  before joining biomark capital dr axenovich was a director at burrill  company where he was responsible for sourcing evaluating and executing investment transactions previously sergey managed the cancer drug discovery program and associated corporate collaborations at ppd he began his research career at genome therapeutics subsequently he received his mba from the university of california berkeley haas school of business sergey has a phd in molecular genetics from the university of illinois chicago and an undergraduate degree in molecular biology from moscow universitydavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei joshua zelig joshua zelig joshua zeligdirectorjoshua zelig joined biomark capital in november  prior to joining the company mr zelig was a director at burrill  company and an associate partner at gbp capital a greenwich connecticutbased healthcare venture firm in that capacity he was responsible for sourcing evaluating and executing investment transactions and new business opportunities additionally mr zelig managed the firm’s intellectual property portfolios oversaw the company’s operations and worked closely with portfolio companies in setting and delivering strategic objectivespreviously mr zelig was an equity research associate at morgan stanley where he covered biotech and consumer stocks he later worked in real estate management acquisition and due diligence on behalf of a number of large private real estate companies as well as public reitsmr zelig is a graduate of yeshiva university sy syms school of business where he received a bachelor of science in financedavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei janos redei janos redei janos redeientrepreneurinresidencedr redei is an entrepreneurinresidence with two decades of experience in healthcare technology the pharmaceutical industry and academia he is also cofounder and cto of idx inc a neurofocused big data analytics company dr redei is a former university of california san francisco faculty member and holds an md as well as a phd in applied neuroinformatics he comes to biomark capital following stints at burrill  company and rochegenentech a leader in personalized healthcarepreviously dr redei headed clinical and imaging informatics at roche for all six therapeutic areas globally including cns at roche he was instrumental in developing a number of groupwide emerging it strategies and implemented the company’s first forays into ondemandcloud computing for clinical applications and digital health he also led the informatics effort of a consortium of five pharma companies to enable disease understanding incorporating biosample imaging and clinical data sources from around the globedavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei about — biomark capital about scroll down about aboutbiomark capital is a venture capital and private equity firm comprised of experienced professionals with over  years of combined investment experience generating superior returnsa confluence of events is changing healthcare globally and worldwide healthcare spending continues to grow at a rapid pace biomark capital believes now is a compelling time to invest in game changing technologies that can broaden the foundation of healthcare practice change the face of patient care improve quality of life and generate superior returns for our investors our focusimpact global healthcare by investing our capital and expertise on the most promising and bestinclass life science companies biomark capital’s primary investment focus is in north america along with a specific focus in russia taiwan india and china our initial investments typically range from  million dollars with key investment criteria including・       highly disruptive innovation・       large clinical unmet medical need・       freedomtooperate  large barriers to entry・       established proofofconcept・       strong management team our investment strategypartner with entrepreneurs to develop establish and build groundbreaking platform technologies into highly successful companies we focus on innovation across the healthcare spectrum including・       therapeutics and medical devices・       molecular diagnostics and healthcare delivery・       information technology exits and ipos — biomark capital adma biologics nasdaq adma scroll down adma biologics nasdaq adma adma biologics nasdaq adma is a late stage biopharmaceutical company that develops manufactures and intends to market specialty plasmabased biologics for the treatment and prevention of certain infectious diseases admas targeted patient populations include immunecompromised individuals who suffer from an underlying immune deficiency disorder or who may be immunesuppressed for medical reasons admas product candidates are intended to be used by physician specialists focused on caring for immunecompromised patients with infectious diseasesadma also operates adma biocenters an fdalicensed ghacertified source plasma collection facility which provides a portion of blood plasma for the manufacture of its lead product candidate rion october   adma biologics announced the closing of its previously announced initial public offering of  shares of its common stock at a public offering price of  per shareread more  adma biologics nasdaq admaflexible stenting solutions jhl biotech twem juno therapeutics nasdaqjunolentigenwavetec vision  flexible stenting solutions flexible stenting solutions flexible stenting solutions fss is a new jersey based private company developing and commercializing flexible strong and durable stents that are built on a proprietary flexstent® technology platform and a unique delivery system the company’s broad product platform includes thirdgeneration flexible peripheral arterial venous neurovascular and biliary stents the fss stents offer advantages over currently available stents including greater stent flexibility improved scaffolding and radial strength and greater fracture and kink resistance the company’s reconstrainable stent and delivery system offers a unique game changing technology to the peripheral stent market flexible stenting solutions was acquired by cordis corporation a division of johnson  johnson on march  read more    adma biologics nasdaq admaflexible stenting solutions jhl biotech twem juno therapeutics nasdaqjunolentigenwavetec vision      jhl biotech twem  jhl biotech twem  jhl biotech twem  was founded in  with a vision of making biopharmaceuticals affordable and accessible to all patients through manufacturing innovation to achieve this vision jhl will provide worldclass process development and manufacturing services in asia to companies developing and commercializing highquality affordable biologic medicines jhl is leveraging the latest process and engineering technologies to reduce the complexity and cost of mammalian cell culture manufacturing these technologies will be incorporated into worldclass biologics api manufacturing facilities in asia that comply with us eu and ich cgmp regulations and guidelinesled by an experienced team of genentech and amgen veterans and funded by toptier venture capital firms including kleiner perkins caufield  byers kpcb sequoia capital biomark capital and cdib jhl is uniquely positioned to deliver manufacturing solutions to its worldwide partnerson september   jhl biotech announced its public listing on taiwan emerging stock boardread more  adma biologics nasdaq admaflexible stenting solutions jhl biotech twem juno therapeutics nasdaqjunolentigenwavetec vision  juno therapeutics nasdaq juno juno therapeutics nasdaq juno juno therapeutics nasdaq juno is focused on revolutionizing medicine by reengaging the body’s immune system to treat cancer founded on the vision that the use of human t cells as therapeutics will drive one of the next important phases in medicine the company is developing cellbased cancer immunotherapies based on its chimeric antigen receptor car and highaffinity t cell receptor tcr technologies to genetically engineer t cells to recognize and kill cancer cells juno therapeutics has shown compelling evidence of tumor shrinkage in clinical trials using multiple cellbased product candidates to address refractory bcell lymphomas and leukemias longer term the company aims to develop its cellbased platform to include additional product candidates to address a broad range of cancers and human diseaseson december   juno therapeutics announced the closing of its initial public offering of  million shares of common stock at a price to the public of  per share which includes the exercise in full by the underwriters of the offering of their option to purchase  million sharesread more  adma biologics nasdaq admaflexible stenting solutions jhl biotech twem juno therapeutics nasdaqjunolentigenwavetec vision  lentigen lentigen lentigen is a diversified biologics company focused on the development and commercialization of breakthrough treatments for human disease lentiviral vectors lv the companys technology platform are widely recognized by the scientific community as the most efficient method for delivery of genetic sequence information into cells to reprogram their function the ability to efficiently and stably reprogram mammalian cells has numerous uses in biotechnology and biomedicine including drug discovery target validation biologics manufacturing and cellular therapies lentigen sold its lentiviral vector manufacturing business and related assets to miltenyi biotec on august  read more    adma biologics nasdaq admaflexible stenting solutions jhl biotech twem juno therapeutics nasdaqjunolentigenwavetec vision    wavetec vision wavetec vision wavetec is committed to developing and providing innovative wavefront measurement technology for cataract surgeons wavetecs revolutionary ora system® provides realtime intraoperative refractive information to ophthalmologists worldwide allowing them to deliver the best possible vision for their cataract patientson august   alcon the global leader in eye care and the second largest division of novartis group announced that the company has entered into an agreement to acquire wavetec visionread more    adma biologics nasdaq admaflexible stenting solutions jhl biotech twem juno therapeutics nasdaqjunolentigenwavetec vision     contact — biomark capital contact contact usagreenwich ct steamboat roadsuite greenwich ct phone   fax      san francisco ca montgomery streetsuite san francisco ca phone   fax     russia krasnopresnenskaya nabworld trade centerentrance  office moscow russiaphone    portfolio — biomark capital adma biologics nasdaq adma scroll down adma biologics nasdaq adma adma biologics nasdaq adma is a late stage biopharmaceutical company that develops manufactures and intends to market specialty plasmabased biologics for the treatment and prevention of certain infectious diseases admas targeted patient populations include immunecompromised individuals who suffer from an underlying immune deficiency disorder or who may be immunesuppressed for medical reasons admas product candidates are intended to be used by physician specialists focused on caring for immunecompromised patients with infectious diseasesadma also operates adma biocenters an fdalicensed ghacertified source plasma collection facility which provides a portion of blood plasma for the manufacture of its lead product candidate rivisit website  adma biologics nasdaq admabetter doctorflexible stenting solutionshypermed imagingidxjhl biotech twem juno therapeutics nasdaq junoopus biostrand life scienceswavetec visionwhiteglove health  better doctor better doctor betterdoctor is a digital health marketplace startup revolutionizing the way consumers search for and discover highly qualified doctors with  billion medical appointments occurring annually  thousand medical practices and hundreds of insurance plans in the us healthcare system the process of finding the right doctor and booking medical appointments is very inefficient and lacks transparency by aggregating disparate sets of healthcare and consumer data betterdoctor is creating an analytics engine that verifies the quality of the doctors and powers betterdoctors mobile and web apps which provide consumers personalized recommendations of the best doctors in a matter of minutes and with just a handful of clicks eliminating the need to spend hours manually searching through online directories and verifying availability one by onevisit website     adma biologics nasdaq admabetter doctorflexible stenting solutionshypermed imagingidxjhl biotech twem juno therapeutics nasdaq junoopus biostrand life scienceswavetec visionwhiteglove health     flexible stenting solutions flexible stenting solutions flexible stenting solutions fss is a new jersey based private company developing and commercializing flexible strong and durable stents that are built on a proprietary flexstent® technology platform and a unique delivery system the company’s broad product platform includes thirdgeneration flexible peripheral arterial venous neurovascular and biliary stents the fss stents offer advantages over currently available stents including greater stent flexibility improved scaffolding and radial strength and greater fracture and kink resistance the company’s reconstrainable stent and delivery system offers a unique game changing technology to the peripheral stent market flexible stenting solutions was acquired by cordis corporation a division of johnson  johnson on march  read more     adma biologics nasdaq admabetter doctorflexible stenting solutionshypermed imagingidxjhl biotech twem juno therapeutics nasdaq junoopus biostrand life scienceswavetec visionwhiteglove health      hypermed imaging hypermed imaging hypermed is developing hyperspectral imaging for medical applications the technology originally developed for military surveillance provides an advanced form of spectroscopy that provides a twodimensional tissue oxygenation map the company has developed a new product using the same breakthrough imaging technology as used in its oxyvu™ system hypermed’s new product called hyperview™ is fda k cleared hyperview is designed to deliver the same diagnostic information in a smaller more portable configuration multiple published studies have demonstrated the clinical utility of oxyvu for the diagnostic assessment of wound healing diabetic foot ulcers and amputation planning technology has been in service since  and has been shown in published clinical research to effectively assess oxyhemoglobin deoxyhemoglobin and oxyhemoglobin saturation in superficial tissue for a number of key healthcare applicationsthe market opportunity for the clinical diagnostic applications for hyperspectral imaging represent a multibillion market visit website     adma biologics nasdaq admabetter doctorflexible stenting solutionshypermed imagingidxjhl biotech twem juno therapeutics nasdaq junoopus biostrand life scienceswavetec visionwhiteglove health     idx idx idx is developing a multimodal cloudbased diagnostic platform for the assessment of neurological disorders the platform will provide quantitative digital assessments of a number of biomarkers that are indicative of brain health with the goal of providing a personalized longitudinal brain record for healthy individuals and patients    adma biologics nasdaq admabetter doctorflexible stenting solutionshypermed imagingidxjhl biotech twem juno therapeutics nasdaq junoopus biostrand life scienceswavetec visionwhiteglove health    jhl biotech twem  jhl biotech twem  jhl biotech twem  was founded in  with a vision of making biopharmaceuticals affordable and accessible to all patients through manufacturing innovation to achieve this vision jhl will provide worldclass process development and manufacturing services in asia to companies developing and commercializing highquality affordable biologic medicines jhl is leveraging the latest process and engineering technologies to reduce the complexity and cost of mammalian cell culture manufacturing these technologies will be incorporated into worldclass biologics api manufacturing facilities in asia that comply with us eu and ich cgmp regulations and guidelinesled by an experienced team of genentech and amgen veterans and funded by toptier venture capital firms including kleiner perkins caufield  byers kpcb sequoia capital biomark capital and cdib jhl is uniquely positioned to deliver manufacturing solutions to its worldwide partnersvisit website    adma biologics nasdaq admabetter doctorflexible stenting solutionshypermed imagingidxjhl biotech twem juno therapeutics nasdaq junoopus biostrand life scienceswavetec visionwhiteglove health    juno therapeutics nasdaq juno juno therapeutics nasdaq juno juno therapeutics nasdaq juno is focused on revolutionizing medicine by reengaging the body’s immune system to treat cancer founded on the vision that the use of human t cells as therapeutics will drive one of the next important phases in medicine the company is developing cellbased cancer immunotherapies based on its chimeric antigen receptor car and highaffinity t cell receptor tcr technologies to genetically engineer t cells to recognize and kill cancer cells juno therapeutics has shown compelling evidence of tumor shrinkage in clinical trials using multiple cellbased product candidates to address refractory bcell lymphomas and leukemias longer term the company aims to develop its cellbased platform to include additional product candidates to address a broad range of cancers and human diseasesvisit website    adma biologics nasdaq admabetter doctorflexible stenting solutionshypermed imagingidxjhl biotech twem juno therapeutics nasdaq junoopus biostrand life scienceswavetec visionwhiteglove health   opus bio inc opus bio inc opus bio formerly lentigen corporation is a diversified biologics company focused on the development and commercialization of breakthrough treatments for human disease lentiviral vectors lv the companys technology platform are widely recognized by the scientific community as the most efficient method for delivery of genetic sequence information into cells to reprogram their function the ability to efficiently and stably reprogram mammalian cells has numerous uses in biotechnology and biomedicine including drug discovery target validation biologics manufacturing and cellular therapiesopuss most advanced clinical candidate is a tcell chimeric antigen receptor cellular therapy targeting cd for hematological malignancies in december  the company has entered into an agreement to license the cd program to juno therapeutics nasdaqjuno phase i clinical study for this compound is enrolling and treating patients opus bio has also secured the rights to other proprietary antigens that combined with its lentiviral vector may have broad applicability across epithelial cancers including colon smallcell lung ovarian breast cancer stomach and esophageal among othersread more      adma biologics nasdaq admabetter doctorflexible stenting solutionshypermed imagingidxjhl biotech twem juno therapeutics nasdaq junoopus biostrand life scienceswavetec visionwhiteglove health     strand life sciences strand life sciences strand life sciences provides bioinformatics solutions with advanced visualization predictive systems modeling data integration and scientific context management components to transform raw data into actionable insights the company employs  people mostly in bangalore india and services both the research and clinical markets strand enjoys three advantages over the competition globally superior software analytics superior curation of gene variants and a major cost advantage for dna test interpretation when combined strand is finding a rapidly growing demand for its strandomics software platform which hospitals and service providers can use to service their patients and healthcare clients with every sequence and gene test the company’s cloud database gets more valuable with related metadata which can be used to improve future analytics thereby creating an additional demand for strandomicsstrand has developed the most advanced software for analyzing dna sequences today  research institutions worldwide use strand’s software under the product names genespring marketed by agilent and avadis marketed by strand the company reached profitability in  and in early  the company began to service the clinical market in india it opened its own dna sequence and gene panel wet lab in bangalore india and in december the company opened a lab which it operates in the bed mazumdarshaw cancer center in bangalore by the end of  strand was servicing the gene testing and dna sequence analysis needs of over  hospitals in india and in  it has begun to expand into the us marketvisit website     adma biologics nasdaq admabetter doctorflexible stenting solutionshypermed imagingidxjhl biotech twem juno therapeutics nasdaq junoopus biostrand life scienceswavetec visionwhiteglove health     wavetec vision wavetec vision wavetec is committed to developing and providing innovative wavefront measurement technology for cataract surgeons wavetecs revolutionary ora system® provides realtime intraoperative refractive information to ophthalmologists worldwide allowing them to deliver the best possible vision for their cataract patientson august   alcon the global leader in eye care and the second largest division of novartis group announced that the company has entered into an agreement to acquire wavetec visionread more     adma biologics nasdaq admabetter doctorflexible stenting solutionshypermed imagingidxjhl biotech twem juno therapeutics nasdaq junoopus biostrand life scienceswavetec visionwhiteglove health    whiteglove health whiteglove health whiteglove’s complete health solution™ provides a comprehensive suite of technologyenabled health and wellness services – including biometrics wellness coaching acute care telemedicine chronic care and onsite services – delivered by our clinical team  this service combined with powerful webbased portals for the member and employer provide the capabilites required to monitor and improve health and wellness because whitegloves solution leverages a single view of the patient and is able to clinically intervene when care is needed we eliminate the complexities and flaws of current wellness and population health management strategiesfounded on the idea think differently about healthcare and delivering an exceptional healthcare experience whiteglove empowers employees and dependents to better manage their own health and wellnesssvisit website     adma biologics nasdaq admabetter doctorflexible stenting solutionshypermed imagingidxjhl biotech twem juno therapeutics nasdaq junoopus biostrand life scienceswavetec visionwhiteglove health  bryant fong — biomark capital bryant fong bryant e fongmanaging directormr fong joined biomark capital in  prior to biomark capital mr fong was a managing director and general partner at burrill  company where he spent almost  years investing in and managing investments in private and public companies in the biotechnology industry some of mr fong’s recent investments include pharmasset vrus novadaq technologies nvdq galapagos glpg ceptaris therapeutics acquired by actelion and ferrokin biosciences acquired by shire prior to joining burrill  company mr fong held positions as a research scientist with two early stage biotechnology companies located in the san francisco bay area mr fong currently serves on the boards of directors of a number of life science companies including adma biologics adma neos therapeutics neos jhl biotech tt and idx  mr fong earned his bachelors degree with honors in molecular and cell biologybiochemistry from the university of california berkeleydavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei biomark capital management co llc company profile  bloomberg feedback biomark capital management co llc private company company profile sector financials industry asset management subindustry private equity biomark capital management co llc operates as a venture capital and private equity firm the company invests in healthcare and life science companies biomark capital serves clients worldwide corporate information address  steamboat road suite  greenwich ct  united states phone  fax  web url wwwbiomarkcapitalcom board members managing director company bryant fong burrill venture capital from the web key executives david s wetherell managing partner douglas d lind managing director bryant fong managing director sergey axenovich director joshua zelig director sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data biomark capital management co llc  greenwich  ct  company information products resources my account talk to a db advisor  business directory ct greenwich investors nec investors nec biomark capital management co llc b biomark capital management co llc claim this business  steamboat rd ste  greenwich ct  get directions   wwwbiomarkcapitalcom business info founded  incorporated annual revenue  employee count  industries investors nec contacts david wetherell contact business your email address subject message send message company summary biomark capital management co llc is located at  steamboat rd ste  in greenwich and has been in the business of investors nec since  verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   b view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocalcom mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call  to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc  all rights reserved bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version biomark capital fund iv lp  portfolio company  rusnano rosnano порусски feedback sign in rusnano corporation all news and events items catalogue of projects investment strategy rusnano corporation fund for infrastructure and educational programs rusnano structure and governing bodies annual and financial reporting contact us subsidiaries rusnano usa inc rusnano israel ltd   all news and events items rusnano news anatoly chubais column media about rusnano corporate identity rss  email subscribe     catalogue of projects portfolio companies     investment strategy applicants technology roadmaps     rusnano and the ministry of science and technology of china signed a cooperation agreement nominations submission for rusnanoprize  is opened having got double return of investments rusnano exits the magnesium oxide and hydroxide production project russia and iran have agreed to cooperate in the field of nanoproduct certification hide main catalogue of projects portfolio companies portfolio companies biomark capital fund iv lp biomark capital management co llc shareholders in portfolio company  limited partners rusnano other partners industry sector  special funds production location  usa russian federation investment started   total budget   bln rubles coinvestment by rusnano   bln rubles biomarkcapitalcom facilitating transfer of technology to russia through equity capital investments and contract manufacturing this venture fund in medicine and biotechnology will invest primarily in companies in midstage development facilitating transfer of western nanotechnology to russia and placement of contract production and services in the country through the establishment of joint businesses companies developing innovative drugs diagnostic medical equipment and medical and industrial biotechnology will be the priorities for the fund’s investment the products and technologies of portfolio companies will be targeted toward resolving vitally important issues for russia’s population particularly socially significant diseases areas in which the fund invests development and market promotion of drugs for treatment of cancers cardiovascular and ophthalmic diseases diabetes mellitus psychic and autoimmune disorders injuries socially significant infection diseases aids hepatitis bacterial infections competitive advantages biomark capital team has a unique experience of venture investments in the field of medicine and biotechnologies consistently high historical performance of investments made by the key team members of the funds managing company rusnanos access to potential coinvestors and partners fund’s lifetime  years technologies and products rusnano was founded in march  as an open joint stock company through reorganization of state corporation russian corporation of nanotechnologies rusnano’s mission is to develop the russian nanotechnology industry through coinvestment in nanotechnology projects with substantial economic potential or social benefit the government of the russian federation owns  percent of the shares in rusnano anatoly chubais is ceo and chairman of the executive board of rusnano work to establish nanotechnology infrastructure and training for nanotechnology specialists formerly conducted by the russian corporation of nanotechnologies has been entrusted to the fund for infrastructure and educational programs a noncommercial fund also established through reorganization of the russian corporation of nanotechnologies for more information please visit wwwrusnanocom  rusnano – a prospekt letiya oktyabryamoscow russia p    f    wwwrusnanocom press office т    e pressrusnanocom  rusnano – usa office sand hill rd –menlo park ca p     israeli officemedinat hayehudim bulding e th floor p o box herzliya pituach  russian officea prospekt letiya oktyabryamoscow russia p    f    e inforusnanocom tweet feedback contact us subscribe rss email our feeds facebook twitter team — biomark capital david wetherell scroll down david wetherell david wetherellmanaging partnerdavid wetherell has spent  years as a ceo in hightech as well as  years in venture capital the last seven of which have been dedicated to biotech and life sciences from  to  he served as both ceo and later chairman of cmgi where he helped build the company from  million in annual revenues to more than  billion and started the first venture capital firm focused on the internet ventures in  due to the mapping of the human genome and demographic trends wetherell turned his attention to the life sciencesin  he started gbp capital a venture capital company focused exclusively on leading edge life sciences wetherell has received numerous awards including ernst  youngs new england entrepreneur of the year in  and recognition as one of money magazines top  investors he obtained his ba in mathematics from ohio wesleyan university and an honorary doctorate from bryant university he currently serves as chairman of lentigen and sits on the boards of numerous other companies including hypermed strand quintess and whiteglove healthdavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei douglas lind douglas lind douglas lindmanaging directordouglas lind joined biomark capital in november  previously he served as managing director at burrill  company and gbp capital a greenwich connecticutbased healthcare venture firm he has more than  years experience in the life sciences industry ranging from the practice of clinical medicine to work as a top tier wall street equity research analyst and venture capitalist throughout his career he has focused on identifying promising disruptive technologies and visionary leadership that offer high value solutions to pressing medical needs he served as senior biotechnology equity research analyst at morgan stanley from  through  and at painewebber from  to  his coverage of large and small capitalization biotechnology companies included amgen biogen celera acquired by quest diagnostics centocor acquired by johnson  johnson chiron acquired by novartis idec pharmaceuticals acquired by biogen imclone acquired by bristolmyers squibb medimmune acquired by astrazeneca agouron acquired by warner lambert axys pharmaceuticals acquired by celera and millenium pharmaceuticals acquired by takeda pharmaceuticalsdr lind is a graduate of the university of iowa college of medicine he served as an attending physician at st elizabeths hospital in boston a major teaching affiliate of tufts university school of medicine where he completed residency training in internal medicine he currently serves on the board of directors of lentigen and hypermed imagingdavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei bryant fong bryant fong bryant e fongmanaging directormr fong joined biomark capital in  prior to biomark capital mr fong was a managing director and general partner at burrill  company where he spent almost  years investing in and managing investments in private and public companies in the biotechnology industry some of mr fong’s recent investments include pharmasset vrus novadaq technologies nvdq galapagos glpg ceptaris therapeutics acquired by actelion and ferrokin biosciences acquired by shire prior to joining burrill  company mr fong held positions as a research scientist with two early stage biotechnology companies located in the san francisco bay area mr fong currently serves on the boards of directors of a number of life science companies including adma biologics adma neos therapeutics neos jhl biotech tt and idx  mr fong earned his bachelors degree with honors in molecular and cell biologybiochemistry from the university of california berkeleydavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei sergey axenovich sergey axenovich sergey axenovichdirectorsergey axenovich joined biomark capital in november  before joining biomark capital dr axenovich was a director at burrill  company where he was responsible for sourcing evaluating and executing investment transactions previously sergey managed the cancer drug discovery program and associated corporate collaborations at ppd he began his research career at genome therapeutics subsequently he received his mba from the university of california berkeley haas school of business sergey has a phd in molecular genetics from the university of illinois chicago and an undergraduate degree in molecular biology from moscow universitydavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei joshua zelig joshua zelig joshua zeligdirectorjoshua zelig joined biomark capital in november  prior to joining the company mr zelig was a director at burrill  company and an associate partner at gbp capital a greenwich connecticutbased healthcare venture firm in that capacity he was responsible for sourcing evaluating and executing investment transactions and new business opportunities additionally mr zelig managed the firm’s intellectual property portfolios oversaw the company’s operations and worked closely with portfolio companies in setting and delivering strategic objectivespreviously mr zelig was an equity research associate at morgan stanley where he covered biotech and consumer stocks he later worked in real estate management acquisition and due diligence on behalf of a number of large private real estate companies as well as public reitsmr zelig is a graduate of yeshiva university sy syms school of business where he received a bachelor of science in financedavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei janos redei janos redei janos redeientrepreneurinresidencedr redei is an entrepreneurinresidence with two decades of experience in healthcare technology the pharmaceutical industry and academia he is also cofounder and cto of idx inc a neurofocused big data analytics company dr redei is a former university of california san francisco faculty member and holds an md as well as a phd in applied neuroinformatics he comes to biomark capital following stints at burrill  company and rochegenentech a leader in personalized healthcarepreviously dr redei headed clinical and imaging informatics at roche for all six therapeutic areas globally including cns at roche he was instrumental in developing a number of groupwide emerging it strategies and implemented the company’s first forays into ondemandcloud computing for clinical applications and digital health he also led the informatics effort of a consortium of five pharma companies to enable disease understanding incorporating biosample imaging and clinical data sources from around the globedavid wetherelldouglas lindbryant fongsergey axenovichjoshua zeligjanos redei douglas lind  managing director at biomark capital management co llc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink douglas lind managing director at biomark capital management co llc overview in the news relationships paths education career history boards  committees douglas lind managing director at biomark capital management co llc overview age  born  notable companies tmune therapeutics inc gbp capital lind  co board seats  number of relationships this person is connected to  people in the news see more pr newswire august   lentigen corporation announces sale of lentiviral vector manufacturing business and change of name to opus bio inc relationships see details david wetherell founder  managing partner at biomark capital management co llc boro dropulic founder at opus bio inc michael barnes chief executive officer at spectral image inc ramesh hariharan founder chief executive officer at strand life sciences pvt ltd viswanathan vinay cofounder at strand life sciences pvt ltd j david hansen president chief executive officer  chairman of the board at mabvax therapeutics holdings inc timothy ravenscroft managing director at profit velocity solutions llc philip o livingston director  chief science officer at mabvax therapeutics holdings inc joshua zelig director venture group at burrill  co llc zhihong pan research director at spectral image inc see  more listings with relsci professional start my free trial ➤ see  more paths to douglas lind douglas lind you connections via relationship science douglas lind sync your contacts to see how you can connect with douglas lind start my free trial ➤ see more educational background graduate  the university of iowa the university of iowa is a flagship public research university located in iowa city iowa the university is organized into eleven colleges the university of iowa was founded on february   career history founder current lind  co managing director   current biomark capital management co llc biomark capital management co llc is an american private company located in greenwich ct the firm acts as an alternative investment manager it was founded in  by david s wetherell he has been the ceo since the company founding cofounder current accendx management llc copresident  director current tmune therapeutics inc tmune therapeutics inc provides cancer treatment research and technology development services it focuses on the development of tcell therapies for the treatment of cancer and infectious diseases the firms proprietary cell activation technology is used and administered in patients who are undergoing treatment for leukemia lymphoma and hiv the company was founded by louis p berneman in  and is headquartered in greenwich ct professional current spectral image inc spectral image inc develops imaging technology for biomedical use it offers clinical tools for biological use the company is headquartered in tampa fl managing director   prior burrill  co llc burrill  cos venture capital activities focus exclusively on life science companies whose technologies and products are applicable across range of life science subsectors including  human healthcare therapeutics and diagnosticsdevices  healthwellness  agricultural biotechnology  biofuels and  industrial biotechnology biomaterials and bioprocesses in addition to sector diversification the firm also diversifies across investment stage in general most of their investments are in the startup through mezzanine stage most of the firms investments are made in series a and b rounds they do invest in public entities burrill  co principally invests in the us and europe the firms professionals usually serve on the board of directors of each portfolio company and when necessary assist with operational activities investments tend to average from  million to  million over the life of a companyburrill  cos private equity investments focus on investments in undervalued smallcap and midcap public companies and selected buyouts and spinouts from pharmaceutical biotechnology and other life sciences entities the firm seeks to acquire significant equity positions often through pipes and to optimize opportunities for future equity financing acquisitions and divestitures senior biotechnology equity research analyst    morgan stanley  co llc founded in  morgan stanley  co llc is an secregistered brokerdealer headquartered in new york city the firm is the primary broker subsidiary of morgan stanley nyse ms they are a member of finra morgan stanley  co provides debt and equity services including underwriting ma advice securities dealing and brokerage and trade execution their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industrythe firms sales  trading division offers cash and electronic trading platforms where morgan stanley acts as principal including as a market maker and agent in executing transactions globally in equity and equityrelated products these products include equity swaps options warrants and futures overlying individual securities indices and baskets of securities and other equityrelated products morgan stanleys institutional equity division is a global leader in the origination distribution and trading of equity equitylinked and equityderivative securities their fixed income team deals in a diverse range of products including interest rate and currency products credit products derivatives and commodities research analyst    painewebber inc paine webber and company was an american stock brokerage and asset management firm that was acquired by the swiss bank ubs ag in  the company was founded in  in boston massachusetts managing partner prior gbp capital gbp capital provides venture funding and assistance to early and midstage life science companies they target companies with unique approaches to diagnostics therapeutics and medical devices gbp capital focuses on investing in companies with technologies that leverage and build upon medical breakthroughs as well as other major developments taking place within the lifesciences industry attending physician prior st elizabeths hospital of the third order of st francis the mission of st elizabeths hospital is to minister to those in need of healthcare in response to gods call to serve each other especially the poor in the performance of its mission st elizabeths hospital will foster the values of respect care competence and joy st elizabeths hospital is committed to performing its mission through cooperation with other healthcare providers and the community whenever possible resident in internal medicine prior tufts university  school of medicine tufts university school of medicine is an international leader in innovative medical education and advanced research the school of medicine is renowned for excellence in education in general medicine biomedical sciences special combined degree programs in business health management public health bioengineering and international relations as well as basic and clinical research at the cellular and molecular level boards  committees corporate boards ▾ copresident  director current tmune therapeutics inc tmune therapeutics inc provides cancer treatment research and technology development services it focuses on the development of tcell therapies for the treatment of cancer and infectious diseases the firms proprietary cell activation technology is used and administered in patients who are undergoing treatment for leukemia lymphoma and hiv the company was founded by louis p berneman in  and is headquartered in greenwich ct member board of directors current mabvax therapeutics holdings inc mabvax therapeutics holdings inc is a clinical stage biopharmaceutical company which focuses on discovering and developing innovative vaccine and monoclonal antibodybased therapeutics for the diagnosis and treatment of cancer the company was founded on july   and is headquartered in san diego ca member board of directors current strand life sciences pvt ltd strand life sciences pvt ltd develops software for drug research it has two products personalized cancer treatment and genomic software the company was founded by vijay chandru ramesh hariharan vinay vishwanathan and swamy manohar in  and is headquartered in bangalore india director current spectral image inc spectral image inc develops imaging technology for biomedical use it offers clinical tools for biological use the company is headquartered in tampa fl director current opus bio inc opus bio inc develops and manufactures lentiviral gene delivery technologies its lentiviral vectors lv technology platform is used for delivery of genetic sequence information into cells to reprogram function and to treat epithelial cancers the company was founded by boro dropulic in  and is headquartered in baltimore md director current hypermed imaging inc director prior   hypermed inc hypermed inc develops medical imaging devices the firm provides its services to the vascular surgeons vascular laboratories foot and ankle surgeons podiatrists research organizations and educational institutions the company was founded in  and is headquartered in burlington ma director prior   viragen inc viragen inc is a biotechnology company specializing in the research development and commercialization of natural and recombinant proteinbased drugs designed to treat a broad range of viral and malignant diseases these proteinbased drugs include natural human alpha interferon and monoclonal antibodies viragens strategy also includes the development of avian transgenic technology as a biomanufacturing platform for the largescale costeffective production of therapeutic proteins the firm is located in plantation fl director prior mabvax therapeutics inc mabvax therapeutics inc developed and commercialized immunotherapeutics for the treatment of cancer the company was founded in  and is headquartered in san diego ca director prior flexible stenting solutions inc flexible stenting solutions inc manufactures and distributes medical devices it develops thirdgeneration flexible peripheral arterial venous neurovascular and biliary stents the company was founded by janet w burpee in  and is headquartered in eatontown nj other affiliations douglas lind is affiliated with lind  co biomark capital management co llc accendx management llc tmune therapeutics inc spectral image inc burrill  co llc morgan stanley  co llc painewebber inc gbp capital st elizabeths hospital of the third order of st francis tufts university  school of medicine tmune therapeutics inc mabvax therapeutics holdings inc strand life sciences pvt ltd spectral image inc opus bio inc hypermed imaging inc hypermed inc viragen inc mabvax therapeutics inc flexible stenting solutions inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ f portfolio biomark capital management co llc stock ideas hedge fund trade spotlight high conviction ipo stocks biotech stocks that hedge funds are buying top undervalued stock picks  stocks that matter most to hedge funds stocks validate your stock consensus stock picks realtime insights hedge funds hedge fund portfolios hedge fund managers find your hedge fund match hm pro pro stock screener institutional portfolios institutional investors sign insubscribe nowweeks free trial hedgemindcom   institutional portfolios   biomark capital management co llc    find institutional investor institutional investor browse institutional investors time period activityallnewincreasedunchangeddecreasedsold out security typeallstockoptions put callfixed income top percentileuse this filter to see holdings within a selected percentile portfoliofor example click  to show only holdings in the top  percentile sectorsuse the pull down list to add one or more sectors to the space below and click apply to filter out the holdings that belong to your selected sectorsapply clear select a sector basic industriescapital goodsconsumer durablesconsumer nondurablesconsumer servicesenergyfinancehealth caremiscellaneouspublic utilitiestechnologytransportationnaunidentified stock stylestock style shows hedge fund managers main investment focus in value or growth it is determined based on analysis of portfolio holdings that are part of about  us stocksresetstylemarket caplargevaluemidblendsmallgrowth biomark capital management co llc time period total holdings total value x activities newincreasedunchangeddecreasedsold out top stock holdingstotal  junoadmambvx  hover over a symbol below for details  sec ffilingdetail sortportfolio weight growth or valueposition valuechange ratesectorazgraphjunocomadmacommbvxcom new   hedgemindcom llc all rights reserved site mapdisclaimertermsprivacycontact us biomark capital management company  llc top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active biomark capital management company  llc httpbiomarkcapitalcom • greenwich ct • investment advisor how do i update this listing biomark capital management company  is based out of greenwich biomark capital management company  is a registered investment advisory firm with clients and discretionary assets under management aum of  form adv from  their last reported f filing for q  included  in managed f securities and a top  holdings concentration of  biomark capital management company s largest holding is juno therapeutics inc with shares held of  whalewisdom has at least  f filings in our database for biomark capital management company  summary f holdings ind managers inv advisor info dg insider form  download f summary to excel download f summary to excel create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from biomark capital management company  llc enter your email address below and choose submit your email cancel  top buys name change  top sells name change  f holdings summary stock port juno juno therapeutics inc  adma adma biologics inc  mbvx mabvax therapeutics holding  see all holdings  f activity market value  million prior market value  million new purchases stocks additional purchases stocks sold out of stocks reduced holdings in stocks top  holdings  turnover   turnover alt   time held top quarters time held top quarters time held all quarters  turnover is calculated by taking the  of new holdings initial purchases  the  of positions sold out of not just reduced divided by the total  of holdings for the quarter  alt turnover is calculated by taking either the total mv of new purchases or the mv of securities sold whichever is less divided by the total mv of the fund  f sector allocation over time fund metrics you are limited to the prior  quarters of f filings subscribe to whalewisdom to view all filing data for biomark capital management company  llc portfolio performance top  equalweighted holdings last updated on  performance for q   performance last  quarters  performance metrics stats are not available for the latest quarter backtester use whalewisdoms backtester tool to test how a hypothetical portfolio would have performed with different investment strategies research one or more filers performance and then optimize their portfolios to match your own investment goals start with one of our predefined groups or create your own view the backtesting whitepaper and the getting started page for additional help take a tour save changes to tracked backtest saving generate report at least one fund must be selected before running a backtest  ending sector allocation quarter to view current combined fdg q  f filings q  f filings q  f filings q  f filings q  f filings q  f filings refresh advanced export download csv download excel xlsx download tsv click to see additional filters security types shares calls puts principal changes in holdings new position added to position reduced position closed out position no change ranking is in the top minimum  of shares stock ticker is etf yesno refresh edit columns shares are split adjusted × report an error your name optional your email optional error to report or any other commentsrequired cancel click here to report any possible errors with this listing f filings available   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required × csv export module this will schedule a job to export all requested f holdings data for this filer when completed an email will be sent to the email address you specify containing a link to download the zip file of the csv files you requested output type output all f holdings into a single csv file output all f holdings into separate csv files per quarter columns to include filer name stock name stock ticker quarter date type of security current shares held current market value previous shares held previous market value current  of portfolio previous  of portfolio current rank previous rank change in shares type of change sector f quarters to include       email address to send data to cancel schedule export this lets you look at individual sub managers or subsidiaries within the f filing quarter       manager optionally compare to quarter        manager  number of shares is not splitadjusted view last form adv compilation report on record biomark capital classified as hedge fund  steamboat road suite  greenwich ct     country united states business phone  fax  professional investment advisor data sec registration as  form of organization limited liability company organized in de number of employees other business activities advisor feescompensation amount of client funds and securities total number of clients amount of client funds and securities by related persons total number of clients from related persons disclosures httpbiomarkcapitalcom data above was derived from sec filings schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft product information management software  plytix pricing solutions product information manager product analytics tool about about us blog press contact sign in get started your product content hub manage optimize and distribute your product content from one cloud platform to get to market faster   x features pricing testimonials launch products faster eliminate the time consuming tasks that holds you back launch products x faster by enriching optimizing and distributing product content from one location crosschannel coherence over half of all shoppers research products on multiple channels before making a purchase with consistent quality product information potential customers will become loyal customers turn spreadsheets into workspace the plytix pim takes all the data you have buried in spreadsheets with smart import mapping get a workspace that lets you add text media and define custom attributes errorfree digital asset management make sure all your product and brand assets are organized and easily accessible by your whole team link images videos pdfs and other files to products without needing duplicate content  digital product catalogs create interactive download centers for your catalogs share them via public link or embed them directly onto your website catalogs are enhanced with email notifications so that you know where all your content goes be the master of your content take control of your product content and see the difference in your bottom line rich consistent content plus the efficiency provided by a pim can boost sales by   get the full feature  pricing list experience the difference other pim systems are complicated and expensive plytix offers affordable readytouse product information management software that is simple enough for entire teams to use and powerful enough to support limitless growth     i finally have one place for all of my data thats always updated and available to me no matter where i am mai johansson  mai copenhagen growth estimate price per month number of products no credit card required pay as you grow all features included unlimited users unlimited variations xml template builder digital asset management onboarding assistance available type number of products here enterprise customideal for  products need something different let’s talk all features included fixed price per month dedicated account manager integration support free onboarding helloplytixcom bernhard bangs allé   frederiksberg denmark          solutions multichannel product distribution plytix for brands plytix for retailers software product information manager product analytics tool resources what is pim pim vs dam analytics tool comparison product updates support terms and conditions plytix about us blog press career contact our site uses cookies by continuing to browse this site you are agreeing to our use of cookies more information close